Sort
10,766 grants matching “checkpoint inhibitor”
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$437,443Srikumar P Chellappan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$437,443Srikumar P Chellappan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
ALDH Inhibition as Modulator of Tumor Immunobiology
$437,359Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2021 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers
$437,206Fukun Guo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · CA
The role of transcription elongation defects in immunotherapy resistance in cancers
$437,202Fukun Guo · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · CA
PAIRS: Validating telomerase reverse transcriptase (TERT) as an intrinsic vulnerability toward sensitizing cancer to radiation
$437,187Stephen J. Kron · University Of Chicago · R01 · FY2024 · CA
Targeting ER+ Breast Cancer Through Induced Viral Mimicry
$437,141Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesis
$436,965Marcus A. Ruscetti · Univ Of Massachusetts Med Sch Worcester · R37 · FY2025 · CA
WEE1 inhibition and tumor immunity
$436,922Bin Zhang · Northwestern University At Chicago · R01 · FY2019 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma
$436,886Amaia Lujambio · Icahn School Of Medicine At Mount Sinai · R37 · FY2020 · CA
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer
$436,781Haobin Chen · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$436,727Mei Kong · University Of California-Irvine · R01 · FY2021 · CA
Brain Tumor Immunotherapy
$436,461Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Rare Central Nervous System Cancers Initiative
$436,461Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
$436,454Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
$436,454Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · P50 · FY2021 · CA
Targeting Metabolic Crosstalk in Pancreatic Cancer
$436,431Christopher J. Halbrook · University Of California-Irvine · R37 · FY2024 · CA
Novel regulations of DNA damage repair
$436,368Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Novel regulations of DNA damage repair
$436,368Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$436,322Zhiguo Li · University Of Kentucky · R01 · FY2023 · CA
Role of Erbb3 kinase activity in colorectal tumorigenesis.
$436,262Zhenghe Wang · Case Western Reserve University · R01 · FY2025 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$436,037Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2021 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$436,037Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2020 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$436,026Lei Zheng · Johns Hopkins University · R01 · FY2018 · CA
LILRB modulates tumor microenvironment and promotes tumor progression
$435,587Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2018 · CA